Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 610 participants.
Also called NCT05360446
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 610 participants
- Sponsor
- Registry
-
NCT05360446 -
2021-004601-47
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Chile, China, France, Hungary, India, Ireland, Italy, Japan, South Korea, Spain, Switzerland, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT05360446. Randomized; triple masking; primary purpose treatment. Start 2022-07-08 (actual); primary completion 2026-10-26 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
- Acronym
- V-PLAQUE
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- Inclisiran sodium 300 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct05360446- Content hash
ad6e49679456d4f0548e868ab060202f568a93458d36eda94b5e0b1b4361e060